Sobieszek Grzegorz, Powrózek Tomasz, Mazurek Marcin, Skwarek-Dziekanowska Anna, Małecka-Massalska Teresa
Department of Cardiology, 1st Military Clinical Hospital with the Outpatient Clinic, 20-048 Lublin, Poland.
Department of Human Physiology, Medical University of Lublin, 20-080 Lublin, Poland.
J Clin Med. 2020 Apr 4;9(4):1021. doi: 10.3390/jcm9041021.
Cachexia is an unfavorable metabolic syndrome causing involuntary weight loss followed by muscle wasting, which can lead to the exacerbation of chronic heart failure (CHF), and considerably increases mortality rate among CHF patients. Unfortunately, until now it has not been possible to determine factors that could improve clinical options for cachexia management or enable the identification of patients at risk of its development. We assessed how cachexia conditions in CHF reflect cardiac and laboratory parameters in comparison with non-cachectic patients.
66 women were enrolled to the study group and underwent meticulous screening, according to recent clinical guidelines, in order to enable CHF and cachexia detection. Body composition was evaluated by bioelectrical impedance analysis (BIA) and laboratory tests were supplemented by analysis of plasma circulating irisin.
A negative correlation between irisin concentration and both CRP and TNF-α was recorded ( = -0.362 and = -0.243; < 0.05). Irisin concentration positively correlated with EF% ( = 0.253; = 0.046) and negatively with LVESd, LVEDd and NT-proBNP ( = -0.326, -0.272, and -0.320; < 0.05). Both low levels of circulating irisin and Capacitance of membrane (Cm) were selected as unfavorable factors affecting cachexia in CHF patients (OR = 1.39 and 34.49; < 0.05). Combination of Cm, irisin, CRP and albumin demonstrated sensitivity of 93.3% and specificity of 85.3% (AUC = 0.949) for distinguishing between cachectic and non-cachectic CHF patients.
Selected parameters reliably reflect cachectic conditions in CHF, and the proposed approach for cachexia based on the combined analysis of at least a few non-invasive markers could offer new opportunities for improving clinical outcomes in CHF patients.
恶病质是一种不良代谢综合征,导致非自愿性体重减轻,随后出现肌肉萎缩,可导致慢性心力衰竭(CHF)恶化,并显著增加CHF患者的死亡率。不幸的是,迄今为止,尚未确定能够改善恶病质管理临床选择或识别有恶病质发展风险患者的因素。我们评估了CHF患者的恶病质状况与非恶病质患者相比如何反映心脏和实验室参数。
66名女性被纳入研究组,并根据最新临床指南进行了细致筛查,以检测CHF和恶病质。通过生物电阻抗分析(BIA)评估身体成分,并通过血浆循环鸢尾素分析补充实验室检测。
记录到鸢尾素浓度与CRP和TNF-α均呈负相关(r = -0.362和r = -0.243;P < 0.05)。鸢尾素浓度与EF%呈正相关(r = 0.253;P = 0.046),与LVESd、LVEDd和NT-proBNP呈负相关(r = -0.326、-0.272和-0.320;P < 0.05)。循环鸢尾素水平低和膜电容(Cm)均被选为影响CHF患者恶病质的不利因素(OR = 1.39和34.49;P < 0.05)。Cm、鸢尾素、CRP和白蛋白的组合对区分恶病质和非恶病质CHF患者的敏感性为93.3%,特异性为85.3%(AUC = 0.949)。
所选参数可靠地反映了CHF患者的恶病质状况,基于至少几种非侵入性标志物联合分析提出的恶病质评估方法可为改善CHF患者的临床结局提供新机会。